Aktuellt
SENASTE
Redeye updates its estimates and fair value range after Physitrack’s stable Q2 2023 report, which came in close to our forecasts. We find the c25% organic growth, combined with effective cost management in the face of ongoing challenging market conditions, to be encouraging. We raise our base case to SEK41(SEK38) per share.
LÄS MER
